Combination alpha-interferon and lamivudine therapy for alpha- interferon-resistant chronic hepatitis B infection: Results of a pilot study

Journal of Hepatology

Volumn 28, Issue 6, 1998, Pages 923-929

  Mutimer, David ^a   Naoumov, Nicolai ^b   Honkoop, Pieter ^c   Marinos, George ^b   Ahmed, Monz ^a   De Man, Robert ^c   McPhillips, Penny ^d   Johnson, Mark ^d   Williams, Roger ^b   Elias, Elwyn ^a   Schalm, Solko ^c  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Alpha interferon; Hepatitis B virus; Lamivudine

Indexed keywords

LAMIVUDINE; RECOMBINANT ALPHA2B INTERFERON; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032101831     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80338-3     Document Type: Article

References (23)

1. Cui L, Yoon S, Schinazi RF, Sommadossi J-P. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-spD-arbinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest. 95:1995;555-563.
2. Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med. 333:1995;1662-1669.
3. Benhamou Y, Dohin E, Lunel-Fabiani F, Poynard T, Huraux JM, Katlama C, et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet. 345:1995;396-397.
4. de Man RA, Schalm SW, Main J, Thomas HC, Fevery J, Nevens F, et al. A dose ranging study to determine the antiviral activity and safety of lamivudine (2′-deoxy-3′-thiacytidine) in patients with chronic hepatitis B infection. Gut. 34:1993;5. (Suppl).
5. Nevens F, Tyrell DL, de Man RA, Main J, Beranek P, Sidar S, et al. A 6-month dose-ranging study of the safety and efficacy of lamivudine in chronic hepatitis B[abstract]. J Hepatol. 23:1995;91. (Suppl).
6. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B: a meta-analysis. Ann Intern Med. 119:1993;312-323.
7. Janssen HLA, Schalm SW, Berk L, de Man RA. Repeated courses of alpha-interferon for treatment of chronic hepatitis type B. J Hepatol. 17:1993;47-51. (suppl).
8. Berk L, Schalm SW, de Man RA, Heytink R.A., Berthelot P, Brechot C, et al. Failure of acyclovir to enhance the antiviral effect of alpha lymphoblastoid interferon on Hbe-seroconversion in chronic hepatitis B. A multi-centre randomised controlled trial. J Hepatol. 14:1992;305-309.
9. Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y. Pilot study of ribavirin and interferon-beta for chronic hepatitis B. Hepatology. 18:1993;258-263.
10. Janssen HLA, Berk L, Heijtink RA, ten Kate FJW, Schalm SW. Interferon-alpha and zidovudine combination therapy for chronic hepatitis B: results of a randomised, placebo-controlled trial. Hepatology. 17:1993;383-388.
11. Fried MW, Fong T-L, Swain MG, Park Y, Beames MP, Banks SM, et al. Therapy of chronic hepatitis B with a 6-month course of ribavirin. J Hepatol. 21:1994;145-150.
12. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 333:1995;1657-1661.
13. Harker AJ, Evans GL, Hawkley AE, Morris DM. Determination of lamivudine in serum. J Chromatogr. 657:1994;227-232.
14. Heinzel G, Woloszczak R, Thomann P. TOPFIT 2.0. Pharmacokinetic and pharmacodynamic data analysis system. 1993;Gustav Fischer, Stuttgart.
15. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 334:1996;1422-1427.
16. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology. 10:1989;761-763.
17. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomised, controlled trial of interferon alfa-2b alone and after prednisolone withdrawal for the treatment of chronic hepatitis B. N Engl J Med. 323:1990;295-301.
18. Garcia G, Smith CI, Weissberg JI, Eisenberg M, Bissett J, Nair PV, et al. Adenine arabinoside monophosphate (vidaribine phosphate) in combination with human leukocyte interferon in the treatment in chronic hepatitis B. Ann Intern Med. 107:1987;278-5.
19. Radwanski E, Perentesis G, Jacobs S, Oden E, Affrime M, Symchowicz S, et al. Pharmacokinetics of interferon alpha-2b in healthy volunteers. J Clin Pharmacol. 27:1987;432-435.
20. Van Leeuwen R, Lange JMA, Hussey EK. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase 1 study. AIDS. 6:1992;1471-1475.
21. Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis. 9:1989;273-277.
22. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine, an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 333:1995;1099-1105.
23. Honkoop P, de Man RA, Scholte HR, Zondervan PE, van der Berg JWO, Rademakers LHPM, et al. Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B. Hepatology. 26:1997;211-215.